Novartis announces anti-PD-1 tislelizumab accepted by EMA for regulatory review in esophageal and lung cancers

PRESS RELEASE Corporate Announcements

19/05/2022

Novartis AG

Basel, April 6, 2022 — Novartis today announced that the European Medicines Agency (EMA) validated Marketing Authorization Applications (MAAs) for the immune checkpoint inhibitor tislelizumab for adults with: - Locally advanced or metastatic, squamous or non-squamous non-small cell lung cancer (NSCLC) as first-line treatment in combination with chemotherapy, - Locally advanced or metastatic NSCLC as monotherapy after prior chemotherapy, and - Unresectable, recurrent, locally advanced or metastatic esophageal squamous cell carcinoma (ESCC) as monotherapy after prior chemotherapy. Tislelizumab is a humanized IgG4 anti-PD-1 monoclonal antibody being developed both as a monotherapy and in combination with other therapies.

Related News

ความสำเร็จของการพัฒนา bending magnet ขนาดเล็กสำหรับฉายลำแสงโปรตอนโดยใช้เทคโนโลยี superconducting

B dot Medical Inc. (สำนักงานใหญ่: Edogawa-ku, Tokyo, ประธาน: Takuji Furukawa จากนี้จะเรียกแทนว่า B dot Medical) ได้ดำเนินการทดสอบความสามารถในการเป็น s...

06/07/2021

PRESS RELEASE Product Launch

AstraZeneca aims to redefine liver, biliary tract and prostate cancer treatment with practice-changing Imfinzi and Lynparza data at ASCO GI and GU

AstraZeneca will present new data in liver, biliary tract and prostate cancers illustrating its ambition to revolutionise cancer care at the 2022 Amer...

18/01/2022

PRESS RELEASE Corporate Announcements

Molecular landscape of multi-step virus carcinogenesis revealed by multi-modal single-cell analysis

A joint research group led by Dr. Keisuke Kataoka at Keio University / National Cancer Center Japan has completed a comprehensive multi-modal single-c...

13/09/2021

PRESS RELEASE Research Findings

Janssen Announces Health Canada Approval of RYBREVANT® (amivantamab), the First and Only Targeted Treatment for Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

Toronto, ON, April 4, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that Health Canada has issued a Notice of Compl...

05/04/2022

PRESS RELEASE Corporate Announcements

ASEC Frontier (Thailand) Co., Ltd

Address : 1 Empire Tower, Unit 1509,1710

15th,17th floor South Sathorn road Yannawa

Sathorn Bangkok, Thailand 10120

Tel : +662-118-0873

Email : info@medical-leaders-thailand.com

Website : www.asec-frontier.com

 

Contact Us